cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30772794
title: A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19

description: Cancer patients face a higher risk of adverse effects from coronavirus disease 2019 (COVID-19) compared to the general population. However, the safety of restarting antitumor therapy following COVID-19 recovery remains unclear. In this prospective, multicenter study conducted between January 1 and 30 March 2023, 419 eligible cancer patients who had recovered from COVID-19 were screened across four medical centers. The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) during the first cycle of antitumor therapy resumed within 3 months after COVID-19 recovery. Changes in clinical laboratory parameters were assessed as secondary endpoints. A total of 270 eligible participants were included in this study. The common grade 3 or worse TEAEs were fatigue (3.3%), anemia (1.1%), leukopenia (0.7%), and elevated alanine transaminase (0.3%). No severe cardiac toxicity and significant abnormalities on the chest computed tomography (CT) were observed. D-dimer and cardiac troponin I (cTNI) were significantly increased after treatment (<i>p</i> &lt; 0.05). Increased inflammatory cytokines of peripheral blood could be observed after administration of oxaliplatin and trastuzumab. Restarting systemic antitumor therapy in solid tumor patients after COVID-19 recovery is generally safe. Systemic inflammatory and coagulation function of patients should be monitored during treatment. There have been very few studies so far that closely followed Chinese cancer patients recovering from coronavirus disease 2019 (COVID-19) to see how safe for them to restart cancer treatment. Our research, the multicenter, observational study shows that restarting treatment is generally safe, even for patients with advanced cancer. We did not observe any serious heart or lung side effects. However, we did notice increases in certain blood markers related to inflammation and clotting after treatment. These changes likely reflect the body’s response to having had COVID-19. We recommend monitoring these blood markers during treatment to keep patients safe.
DOI: 10.6084/m9.figshare.30772794.v1
title: A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19

description: Cancer patients face a higher risk of adverse effects from coronavirus disease 2019 (COVID-19) compared to the general population. However, the safety of restarting antitumor therapy following COVID-19 recovery remains unclear. In this prospective, multicenter study conducted between January 1 and 30 March 2023, 419 eligible cancer patients who had recovered from COVID-19 were screened across four medical centers. The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) during the first cycle of antitumor therapy resumed within 3 months after COVID-19 recovery. Changes in clinical laboratory parameters were assessed as secondary endpoints. A total of 270 eligible participants were included in this study. The common grade 3 or worse TEAEs were fatigue (3.3%), anemia (1.1%), leukopenia (0.7%), and elevated alanine transaminase (0.3%). No severe cardiac toxicity and significant abnormalities on the chest computed tomography (CT) were observed. D-dimer and cardiac troponin I (cTNI) were significantly increased after treatment (<i>p</i> &lt; 0.05). Increased inflammatory cytokines of peripheral blood could be observed after administration of oxaliplatin and trastuzumab. Restarting systemic antitumor therapy in solid tumor patients after COVID-19 recovery is generally safe. Systemic inflammatory and coagulation function of patients should be monitored during treatment. There have been very few studies so far that closely followed Chinese cancer patients recovering from coronavirus disease 2019 (COVID-19) to see how safe for them to restart cancer treatment. Our research, the multicenter, observational study shows that restarting treatment is generally safe, even for patients with advanced cancer. We did not observe any serious heart or lung side effects. However, we did notice increases in certain blood markers related to inflammation and clotting after treatment. These changes likely reflect the body’s response to having had COVID-19. We recommend monitoring these blood markers during treatment to keep patients safe.
DOI: 10.6084/m9.figshare.30883923
title: Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial

description: Lack of diversity in clinical trial populations often results in healthcare inequity. This retrospective analysis presents the impact of implementing inclusive research practices on the diversity of the MyTACTIC trial population. Adult patients with advanced solid tumors were enrolled from large academic centers or community cancer clinics and a number of inclusive research practices were implemented to diversify patient recruitment. We summarized race/ethnicity data of the study population related to the sites’ catchment area. Overall, 252 patients were enrolled (83% White). Community clinics represented 95% of screening sites (enrolled 249/252 patients). The proportion of patients from racial/ethnic minorities was generally higher in study centers from ethnically diverse catchment areas. Streamlining the protocol and implementing a free transport scheme to improve patient recruitment yielded positive feedback from site staff; 14 patients (5.5%) used the transportation service. Findings from the MyTACTIC trial suggest that running trials at community oncology sites does not, by itself, increase patient diversity; other efforts are also necessary. NCT04632992.
DOI: 10.6084/m9.figshare.30883923.v1
title: Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial

description: Lack of diversity in clinical trial populations often results in healthcare inequity. This retrospective analysis presents the impact of implementing inclusive research practices on the diversity of the MyTACTIC trial population. Adult patients with advanced solid tumors were enrolled from large academic centers or community cancer clinics and a number of inclusive research practices were implemented to diversify patient recruitment. We summarized race/ethnicity data of the study population related to the sites’ catchment area. Overall, 252 patients were enrolled (83% White). Community clinics represented 95% of screening sites (enrolled 249/252 patients). The proportion of patients from racial/ethnic minorities was generally higher in study centers from ethnically diverse catchment areas. Streamlining the protocol and implementing a free transport scheme to improve patient recruitment yielded positive feedback from site staff; 14 patients (5.5%) used the transportation service. Findings from the MyTACTIC trial suggest that running trials at community oncology sites does not, by itself, increase patient diversity; other efforts are also necessary. NCT04632992.
DOI: 10.6084/m9.figshare.30987534
title: Discovery of 2-phenylethyl chromones as potent and selective CYP1B1 inhibitors

description: Cytochrome P4501B1 (CYP1B1), overexpressed in solid tumours but minimally in healthy tissues, is a promising anticancer target linked to chemoresistance. While CYP1B1 inhibitors can restore drug efficacy, most suffer from limited scaffold diversity and poor selectivity against other CYPs. We identified 2-(2-phenylethyl) chromones as a novel scaffold for anti-CYP1B1 activity and synthesised 24 derivatives with varied ring A/B substituents and established the SAR. Three compounds (<b>CX-6</b>, <b>CX-9</b>, <b>CX-22</b>) showed nanomolar anti-CYP1B1 activity and exceptional selectivity (SI &gt; 230). In CYP1B1-overexpressing cells, the water-soluble and non-cytotoxic <b>CX-9</b> (solubility &gt; 100 μM) dose-dependently reversed docetaxel resistance, achieving efficacy at 50 μM comparable to 20 μM of the CYP1B1 inhibitor α-naphthoflavone (ANF). Molecular docking revealed similar binding modes for <b>CX-9</b> and ANF in CYP1B1’s active site. This work hints 2-(2-phenylethyl) chromones as a natural-derived scaffold for promising CYP1B1 inhibitor development.
DOI: 10.6084/m9.figshare.30987534.v1
title: Discovery of 2-phenylethyl chromones as potent and selective CYP1B1 inhibitors

description: Cytochrome P4501B1 (CYP1B1), overexpressed in solid tumours but minimally in healthy tissues, is a promising anticancer target linked to chemoresistance. While CYP1B1 inhibitors can restore drug efficacy, most suffer from limited scaffold diversity and poor selectivity against other CYPs. We identified 2-(2-phenylethyl) chromones as a novel scaffold for anti-CYP1B1 activity and synthesised 24 derivatives with varied ring A/B substituents and established the SAR. Three compounds (<b>CX-6</b>, <b>CX-9</b>, <b>CX-22</b>) showed nanomolar anti-CYP1B1 activity and exceptional selectivity (SI &gt; 230). In CYP1B1-overexpressing cells, the water-soluble and non-cytotoxic <b>CX-9</b> (solubility &gt; 100 μM) dose-dependently reversed docetaxel resistance, achieving efficacy at 50 μM comparable to 20 μM of the CYP1B1 inhibitor α-naphthoflavone (ANF). Molecular docking revealed similar binding modes for <b>CX-9</b> and ANF in CYP1B1’s active site. This work hints 2-(2-phenylethyl) chromones as a natural-derived scaffold for promising CYP1B1 inhibitor development.
DOI: 10.6084/m9.figshare.30877315
title: Integrative lipophilicity assessment and pharmacokinetic correlation of pyrimidine precursors and artesunate–pyrimidine hybrids: development of QSAR models for anticancer activity and interaction with <i>P</i>-glycoprotein

description: To evaluate chromatographic lipophilicity of novel artesunate–pyrimidine hybrids and precursors using reversed-phase thin-layer chromatography (RP-TLC) and assess plasma protein binding (PPB). The impact of measured and predicted lipophilicity on pharmacokinetic descriptors was evaluated. Principal component analysis (PCA) explored relationships among lipophilicity, PPB, and physicochemical descriptors. Quantitative structure–activity relationship (QSAR) and partial least squares (PLS) models linked molecular descriptors to cytotoxicity and resistance modulation in nonsmall cell lung cancer (NSCLC) cells. Lipophilicity was measured by RP-TLC. PPB was determined using human serum albumin (HSA)-modified high-performance liquid chromatography (HPLC). PCA characterized physicochemical–pharmacokinetic correlations. Cytotoxicity in sensitive NCI-H460 and multidrug-resistant (MDR) NCI-H460/R cells was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. QSAR and PLS models identified key descriptors. Lipophilicity strongly influenced adsorption, distribution, and protein binding. Highly lipophilic hybrids showed near-complete HSA binding. Compound 2k lost cytotoxicity in the presence of albumin, whereas 4k retained potency. Models indicated steric and electronic features, alongside lipophilicity, dictate efficacy and <i>P</i>-glycoprotein (<i>P</i>-gp) interactions, particularly in resistant cells. Lipophilicity and steric/electronic descriptors govern distribution, protein binding, and anticancer activity. Integrating these features enables design of hybrids overcoming <i>P</i>-gp-mediated multidrug resistance, with hybrid 4k emerging as a promising candidate.
DOI: 10.6084/m9.figshare.30877315.v1
title: Integrative lipophilicity assessment and pharmacokinetic correlation of pyrimidine precursors and artesunate–pyrimidine hybrids: development of QSAR models for anticancer activity and interaction with <i>P</i>-glycoprotein

description: To evaluate chromatographic lipophilicity of novel artesunate–pyrimidine hybrids and precursors using reversed-phase thin-layer chromatography (RP-TLC) and assess plasma protein binding (PPB). The impact of measured and predicted lipophilicity on pharmacokinetic descriptors was evaluated. Principal component analysis (PCA) explored relationships among lipophilicity, PPB, and physicochemical descriptors. Quantitative structure–activity relationship (QSAR) and partial least squares (PLS) models linked molecular descriptors to cytotoxicity and resistance modulation in nonsmall cell lung cancer (NSCLC) cells. Lipophilicity was measured by RP-TLC. PPB was determined using human serum albumin (HSA)-modified high-performance liquid chromatography (HPLC). PCA characterized physicochemical–pharmacokinetic correlations. Cytotoxicity in sensitive NCI-H460 and multidrug-resistant (MDR) NCI-H460/R cells was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. QSAR and PLS models identified key descriptors. Lipophilicity strongly influenced adsorption, distribution, and protein binding. Highly lipophilic hybrids showed near-complete HSA binding. Compound 2k lost cytotoxicity in the presence of albumin, whereas 4k retained potency. Models indicated steric and electronic features, alongside lipophilicity, dictate efficacy and <i>P</i>-glycoprotein (<i>P</i>-gp) interactions, particularly in resistant cells. Lipophilicity and steric/electronic descriptors govern distribution, protein binding, and anticancer activity. Integrating these features enables design of hybrids overcoming <i>P</i>-gp-mediated multidrug resistance, with hybrid 4k emerging as a promising candidate.
DOI: 10.5281/zenodo.17933472
title: Structural factors governing alkane substrate specificity in the alkane monooxygenase (AlkB) family
DOI: 10.5281/zenodo.17933473
title: Structural factors governing alkane substrate specificity in the alkane monooxygenase (AlkB) family
DOI: 10.15468/dl.6v88k7
title: Occurrence Download

description: A dataset containing 330784 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Allium runemarkii, Alytes dickhilleni, Alytes muletensis, Alzoniella delmastroi, Ampullaceana pinteri, Anagyris latifolia, Anchusa crispa, Anthemis glaberrima, Argyranthemum lidii, Armeria pseudarmeria, Armeria soleirolii, Asparagus fallax, Atriplex lanfrancoi, Bazzania azorica, Belgrandiella aulaei, Breutelia azorica, Bruchia vogesiaca, Calypogeia azorica, Campanula vidalii, Campylopus flaccidus, Campylostelium strictum, Canariella eutropis, Canariella huttereri, Carlina diae, Centaurea horrida, Centranthus trinervis, Cephaloziella dentata, Chalcides sexlineatus, Chamaemeles coriacea, Cheilolejeunea cedercreutzii, Cheirolophus massonianus, Cicer canariense, Cistus chinamadensis, Cololejeunea madeirensis, Corticeus versipellis, Crambe microcarpa, Crambe pritzelii, Crataegus nigra, Crocidura canariensis, Crocidura zimmermanni, Crocus ilvensis, Daphne rodriguezii, Daucus rouyi, Discula tectiformis, Dracaena draco, Echinodium renauldii, Echinodium setigerum, Echinodium spinosum, Eokochia saxicola, Epipactis cupaniana, Epistrophe leiophthalma, Eumerus canariensis, Eumerus hungaricus, Eumerus longicornis, Eupeodes vandergooti, Euproctus platycephalus, Fratercula arctica, Fritillaria obliqua, Galemys pyrenaicus, Gallotia bravoana, Gallotia intermedia, Genista haenseleri, Geomitra tiarella, Geomitra watsoni, Gesnouinia arborea, Gonepteryx maderensis, Gyraulus stankovici, Hedenasiastrum percurrens, Herbertus azoricus, Heringia adpropinquans, Homalia webbiana, Juniperus cedrus, Lactuca watsoniana, Lampadia webbiana, Lepidozia stuhlmannii, Leptaxis wollastoni, Leptoscyphus porphyrius, Limonium athinense, Limonium chersonesum, Limonium dolihiense, Limonium heraionense, Limonium ikaricum, Limonium kirikosicum, Limonium parosicum, Limonium quinnii, Limonium recticaule, Limonium vravronense, Marstoniopsis macedonica, Micromitrium tenerum, Musschia wollastonii, Myathropa usta, Narcissus willkommii, Obelus discogranulatus, Oestophora calpeana, Onosma tornensis, Osmia maritima, Ovis gmelini, Oxychilus aegopinoides, Pelagodroma marina, Pelekium atlanticum)",
 "BasisOfRecord is one of (Observation, Human Observation, Material sample, Specimen, Unknown evidence, Machine Observation, Occurrence evidence)",
 "Year is greater than or equal to 1971",
 "Year is less than or equal to 2024",
 "HasCoordinate is true"
 ]
}

 The dataset includes 330784 records from 611 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071003-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17640119
title: Dataset for a publication: "Mechanical alloying, an innovative way of zinc preparation for biomaterial applications"

description: General description:

The dataset accompanies the article "Mechanical alloying, an innovative way of zinc preparation for biomaterial applications". It is organized into several subfolders.

 

Further details:

Further details can be found in the README.txt file.

 

Dataset versions:

V1 - original version being submitted on 2025-08-28.
DOI: 10.5281/zenodo.17640120
title: Dataset for a publication: "Mechanical alloying, an innovative way of zinc preparation for biomaterial applications"

description: General description:

The dataset accompanies the article "Mechanical alloying, an innovative way of zinc preparation for biomaterial applications". It is organized into several subfolders.

 

Further details:

Further details can be found in the README.txt file.

 

Dataset versions:

V1 - original version being submitted on 2025-08-28.
DOI: 10.5281/zenodo.18098757
title: Data Archive Supporting: Uptake of CH3OO· by Atmospherically-Relevant Inorganic Solid Surfaces, Durif et al. 2026
DOI: 10.5281/zenodo.18098756
title: Data Archive Supporting: Uptake of CH3OO· by Atmospherically-Relevant Inorganic Solid Surfaces, Durif et al. 2026
DOI: 10.15468/dl.hj884w
title: Occurrence Download

description: A dataset containing 17 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "MediaType is Image",
 "TaxonKey is Campanula podocarpa"
 ]
}

 The dataset includes 17 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071033-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.18130800
title: CHOAT JH, ROBERTSON DR (2008) AN ECOLOGICAL SURVEY OF THE ST HELENA AND ASCENSION ISLAND POPULATIONS OF THE JACK (EPINEPHELUS ADSCENSIONIS) WITH A REVIEW OF MANAGEMENT OPTIONS.

description:  CHOAT JH, ROBERTSON DR (2008) AN ECOLOGICAL SURVEY OF THE ST HELENA AND ASCENSION ISLAND POPULATIONS OF THE JACK (EPINEPHELUS ADSCENSIONIS) WITH A REVIEW OF MANAGEMENT OPTIONS. 

DOI:10.5281/zenodo.18130800

This report to the Government of St Helena Island is based on the results of fieldwork at St Helena by the authors in 2006. It examines the demography of an important commercial fishery resource at St Helena, that for the “Jack”, Epinephelus adscensionis (Epinephelidae). It compares the demography of that species at St. Helena and the nearby mid-Atlantic island, Ascension Island, which lacks such a commercial fishery and where fieldwork was also conducted in 2006.

The report also compares the demography at both islands of five taxonomically and ecologically diverse species of reef fishes that are not fished at either island. Those species are Acanthurus bahianus (Acanthuridae, Brazil and both islands), Sparisoma strigatum (Labridae: Scarinae, endemic to both islands), Ophioblennius cf atlanticus (Blenniidae, endemic to both islands) and a pair of closely related species, one endemic to each island: Stegastes sanctahelenae at St Helena and S. lubbocki at Ascension (Pomacentridae). This latter group of five species provides information relevant to assessing effects of differences in the island environments and fish assemblages independent of effects due to a commercial fishery.
DOI: 10.5281/zenodo.18130799
title: CHOAT JH, ROBERTSON DR (2008) AN ECOLOGICAL SURVEY OF THE ST HELENA AND ASCENSION ISLAND POPULATIONS OF THE JACK (EPINEPHELUS ADSCENSIONIS) WITH A REVIEW OF MANAGEMENT OPTIONS.

description:  CHOAT JH, ROBERTSON DR (2008) AN ECOLOGICAL SURVEY OF THE ST HELENA AND ASCENSION ISLAND POPULATIONS OF THE JACK (EPINEPHELUS ADSCENSIONIS) WITH A REVIEW OF MANAGEMENT OPTIONS. 

DOI:10.5281/zenodo.18130800

This report to the Government of St Helena Island is based on the results of fieldwork at St Helena by the authors in 2006. It examines the demography of an important commercial fishery resource at St Helena, that for the “Jack”, Epinephelus adscensionis (Epinephelidae). It compares the demography of that species at St. Helena and the nearby mid-Atlantic island, Ascension Island, which lacks such a commercial fishery and where fieldwork was also conducted in 2006.

The report also compares the demography at both islands of five taxonomically and ecologically diverse species of reef fishes that are not fished at either island. Those species are Acanthurus bahianus (Acanthuridae, Brazil and both islands), Sparisoma strigatum (Labridae: Scarinae, endemic to both islands), Ophioblennius cf atlanticus (Blenniidae, endemic to both islands) and a pair of closely related species, one endemic to each island: Stegastes sanctahelenae at St Helena and S. lubbocki at Ascension (Pomacentridae). This latter group of five species provides information relevant to assessing effects of differences in the island environments and fish assemblages independent of effects due to a commercial fishery.
DOI: 10.15468/dl.qq8ex2
title: Occurrence Download

description: A dataset containing 19345 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Ambystoma tigrinum"
 ]
}

 The dataset includes 19345 records from 128 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071034-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.m44yjp
title: Occurrence Download

description: A dataset containing 10218 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Chauna chavaria"
 ]
}

 The dataset includes 10218 records from 125 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071035-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17898547
title: Datased for a publication: "Mechanical Properties of 3D Printed Porous Ti-6Al-4V Alloy for Biomedical Applications"

description: General description:

The dataset accompanies the article "Mechanical Properties of 3D Printed Porous Ti-6Al-4V Alloy for Biomedical Applications". It is organized into several subfolders.

 

Further details:

Further details can be found in the README.txt file.

 

Dataset versions:

V1 - original version being submitted on 2025-08-27.
DOI: 10.5281/zenodo.17898548
title: Datased for a publication: "Mechanical Properties of 3D Printed Porous Ti-6Al-4V Alloy for Biomedical Applications"

description: General description:

The dataset accompanies the article "Mechanical Properties of 3D Printed Porous Ti-6Al-4V Alloy for Biomedical Applications". It is organized into several subfolders.

 

Further details:

Further details can be found in the README.txt file.

 

Dataset versions:

V1 - original version being submitted on 2025-08-27.
DOI: 10.15468/dl.pgnd6k
title: Occurrence Download

description: A dataset containing 6 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "Country is Türkiye",
 "MediaType is Image",
 "TaxonKey is Campanula raveyi"
 ]
}

 The dataset includes 6 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071036-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.